IOVA - What's Going On With Iovance Biotherapeutics Today? | Benzinga
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) stock is trading higher. The company recently announced updated clinical data for treating frontline advanced melanoma.
What Happened: On Thursday, Iovance revealed updated clinical findings for lifileucel in conjunction with pembrolizumab as a treatment for frontline advanced melanoma, as well as implementation data, to be presented at the 2024 ASCO Annual Meeting.
Results from the clinical trial, specifically IOV-COM-202 trial’s Cohort 1A, were published in an abstract ...